All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 69 points (0.4%) at 16,709 as of Monday, Feb. 29, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,159 issues advancing vs. 752 declining with 167 unchanged.

The Health Care sector currently sits up 0.1% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the sector include

Horizon Pharma

(

HZNP

), down 17.0%,

Valeant Pharmaceuticals International

(

VRX

), down 8.6%,

Mylan

(

MYL

), down 2.2%,

Teva Pharmaceutical Industries

(

TEVA

), down 1.5% and

Fresenius Medical Care AG & Co. KGaA

(

FMS

), down 1.4%. Top gainers within the sector include

Biomarin Pharmaceutical

(

BMRN

), up 4.4%,

Alibaba Group

(

BABA

), up 3.7%,

Alexion Pharmaceuticals

(

ALXN

), up 1.0%,

Gilead

(

GILD

), up 0.9% and

Abbott Laboratories

(

ABT

), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3.

Endo International

(

TST Recommends

ENDP

) is one of the companies pushing the Health Care sector lower today. As of noon trading, Endo International is down $9.56 (-18.1%) to $43.38 on heavy volume. Thus far, 7.3 million shares of Endo International exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $42.81-$50.56 after having opened the day at $50.47 as compared to the previous trading day's close of $52.94.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Endo International has a market cap of $11.9 billion and is part of the drugs industry. Shares are down 13.6% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Endo International a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Endo International

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and weak operating cash flow. Get the full

Endo International Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Shire

(

SHPG

) is down $2.88 (-1.8%) to $158.12 on light volume. Thus far, 570,183 shares of Shire exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $157.17-$160.59 after having opened the day at $160.42 as compared to the previous trading day's close of $161.00.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $32.6 billion and is part of the drugs industry. Shares are down 20.6% year-to-date as of the close of trading on Friday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Shire

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Shire Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Express Scripts

(

ESRX

) is down $0.49 (-0.7%) to $70.84 on light volume. Thus far, 990,068 shares of Express Scripts exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $70.11-$71.49 after having opened the day at $70.73 as compared to the previous trading day's close of $71.33.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States, Canada, and Europe. The company operates through two segments, PBM and Other Business Operations. Express Scripts has a market cap of $46.6 billion and is part of the health services industry. Shares are down 18.4% year-to-date as of the close of trading on Friday. Currently there are 8 analysts that rate Express Scripts a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Express Scripts

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Express Scripts Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).